This is an prospective, multicenter, single-arm clinical study.
Age ≥18 years old;
Signed the informed consent and volunteered to join the study with good compliance;
HER2 negative was defined as 0/1+ on standard IHC test; HER2/CEP17 ratio was less than 2.0 or HER2 gene copy number was less than 4.
ER positive and/or PR positive were defined as the proportion of positively stained tumor cells in all tumor cells ≥1%;
Stage IV (metastatic) breast cancer;
Received treatment for the disease, including chemotherapy, endocrine therapy, radiotherapy, immunotherapy, etc.;
Patients who are participating in other intervention studies;
Women with confirmed pregnancy or lactation;
Single group
Bevacizumab
DrugAll subjects enrolled will receive bevacizumab .Subjects continued to take medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or discontinuation of medication at the discretion of the investigator.
PCR
pathologic complete response
ORR
objective response rate
AE Advese Event Advese Event breast conservation rates
Advese Event
BCR breast conservation rates
breast conservation rates
Click on the lead sponsor to view all of their trials.
